Source: Amanda Sealy, WRAL, 11/16/21

 Pfizer announced Tuesday that it is seeking emergency use authorization from the US Food and Drug Administration for its experimental antiviral Covid-19 pill, known as PF-07321332 or Paxlovid. "With more than 5 million deaths and countless lives impacted by this devastating disease globally, there is an urgent need for life-saving treatment options. The overwhelming efficacy achieved in our recent clinical study of PAXLOVID, and its potential to help save lives and keep people out of the hospital if authorized, underscores the critical role that oral antiviral therapies could play in the battle against COVID-19," Albert Bourla, chairman and CEO of Pfizer, said in a statement.

For more of this story, click here.